|
 |
ClofarabineThis page contains recent news articles, when available, and an overview of Clofarabine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Ma un composto che si chiama «clofarabine» sperimentato a Boston su un gruppo di pazienti resistenti, che in Italia sarebbero stati senza speranza, il Giornale, Genzyme Reports Strong Second-Quarter Growth - Jul 23, 2008 Genzyme also expects that the labeling for Clolar(R) (clofarabine) will be expanded by the middle of next year to include its use in treating adult patients FOXBusiness Wall Street News Alert: OCOL Is on the Move! June 23, 2008 - Jun 23, 2008 He is a founder of ILEX(TM) Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). Trading Markets (press release), Oncolin Appoints Member of National Cancer Institute Advisory ... - Jun 23, 2008 He is a founder of ILEX(TM) Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). Centre Daily Times, Rocket-Stocks.com: Stocks that take off like Rockets! Stock Alert ... - Jun 24, 2008 He is a founder of ILEX(TM) Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). Trading Markets (press release), redhotpennystock.com: PGXC, WWEI, QMNM, BIHC, ITUI, OCOL ... - Jun 23, 2008 He is a founder of ILEX(TM) Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). Trading Markets (press release), Preliminary Analyses From Phase 2 Genzyme Study Highlight Efficacy ... - Jun 3, 2008 Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45 Medical News Today (press release), Wall Street News Alert: Breaking Investors Alert for Monday: OCOL ... - Jun 30, 2008 He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). Trading Markets (press release), Stockwire.com: (OTCBB:OCOL) Oncolin Therapeutics, Inc. just ... - Jun 23, 2008 Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved for patients with leukemia). He is founder and the Editor Trading Markets (press release), Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy ... - 02 Jun 2008 Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45 Earthtimes (press release), Genzyme (GENZ) Presents Preliminary Phase 2 Results of Clolar(R) - 02 Jun 2008 Results from the CLASSIC-II clinical trial show that patients with unfavorable prognostic factors who received single agent clofarabine exhibited a 45% StreetInsider.com (subscription), US Oncology Affiliated Physicians Make a Strong Showing in ASCO ... - 02 Jun 2008 Cancer Care Centers of South Texas-Medical Center: Phase II study of single agent clofarabine in previously untreated older adult patients with acute Earthtimes (press release), Market Report -- In Play (GENZ) - 02 Jun 2008 Genzyme announces preliminary analyses from phase 2 study highlight efficacy and safety of clofarabine in older adult AML patients; data show "encouraging" MSN Money Ahead of the Bell: Analysts bullish on Genzyme pipeline - May 8, 2008 Oppenheimer analyst Brian Abrahams said the company presented good results from a midstage trial of clofarabine, a cancer drug. Houston Chronicle, Wachovia expects positive Genzyme data at ASCO - May 15, 2008 Food and Drug Administration and European regulatory approval of its cancer drug clofarabine, a Wachovia Capital Markets analyst said Thursday. Houston Chronicle, Sector Wrap: Celgene, Genentech in ASCO spotlight - May 16, 2008 ..."While we do not expect major movement for GENZ shares on this data, we believe that clofarabine will be a meaningful revenue line in the out-years," CNNMoney.com Allos' PDX Yields Positive Interim Data in PTCL Trial - May 15, 2008 ...s Clolar (clofarabine) was approved in 2004 in pediatric relapsed or refractory lymphoblastic leukemia based on a 20 percent response rate, and in 2005, BioWorld Online, Genzyme Reports Strong First-Quarter Growth - 23 Apr 2008 These include investments in the US launch of Renvela(R) (sevelamer carbonate) and the expanded European introduction of Clolar(R) (clofarabine), PR Newswire (press release), Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year - Feb 14, 2008 The company: Expanded its emerging oncology franchise by securing worldwide rights to its leukemia drug Clolar® (clofarabine) through the acquisition of Lifescience-online, Human cost of drug dilemmas - Jan 31, 2008 Instead, they identified a drug called clofarabine as his only chance. But because the drug had not yet been licensed for the treatment of leukaemia, York Press, Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue - Jan 8, 2008 Genzyme's Oncology franchise is expected to generate approximately $500 million annually by 2011, driven by the use of Clolar(R) (clofarabine) as a FOX News Vion Pharmaceuticals: FDA allows leukemia trial to resume - Jan 10, 2008 Cloretazine's potential competitors include Genzyme's Clolar (clofarabine) which is also in a Phase III trial for the second-line treatment of AML. Trading Markets (press release), High-profit products old and new keep Genzyme on the up - Jan 9, 2008 Oncology is another franchise expected to generate $500 million annually by 2011, driven by Clolar (clofarabine) as a first-line therapy for adult acute Pharma Times (subscription), Bioenvision Shareholders Approve Acquisition by Genzyme Corporation - Oct 22, 2007 ..."We are deeply committed to furthering the clinical development of clofarabine and making it available on a global basis so that patients around the world CNNMoney.com Bioenvision shareholders OK Genzyme buy-out - Oct 23, 2007 Clofarabine was developed in San Antonio by the former ILEX Oncology Inc., which Genzyme bought in 2004. ILEX was subsequently renamed Genzyme Oncology and Bizjournals.com, Bioenvision Stockholders Approve Acquisition By Genzyme - Update ... - Oct 22, 2007 The acquisition is expected to bolster the oncology business of Genzyme by providing exclusive, worldwide rights to clofarabine. In Europe, Bioenvision and RTT News, Bioenvision Shareholders Approve Acquisition by Genzyme - Oct 24, 2007 With its acquisition of Bioenvision, Genzyme gains exclusive, worldwide rights to the cancer drug clofarabine, which is branded as Clolar in the US and FDA news (subscription), Genzyme Reports Strong Earnings Growth in Third Quarter - Oct 24, 2007 The transaction provides Genzyme with worldwide rights for clofarabine, which is currently approved in the United States for the treatment of acute CNNMoney.com Sizing Up Genzyme's Takeover Potential - Nov 15, 2007 The company secured worldwide rights to its leukemia drug clofarabine. Genzyme is conducting studies to expand the drug to other indications such as adult Genetic Engineering News (press release), Bioenvision shareholders give thumbs up to Genzyme buy Mass High ... - Oct 23, 2007 The two companies have jointly developed clofarabine, marketed in Europe to treat a form of leukemia in pediatric patients. It is marketed in the United Bizjournals.com, Genzyme Offer for Bioenvision Approved - Oct 22, 2007 Genzyme hopes the acquisition will enhance its oncology offerings because it will receive exclusive, worldwide rights to clofarabine, a cancer drug Houston Chronicle, Bioenvision, Genzyme get OK to reopen merger vote - 14 Oct 2007 ...a $16.8 million loss on $3.18 billion in 2006 sales, agreed to buy New York-based Bioenvision to gain exclusive rights to the leukemia drug clofarabine. The News Journal, Court allows Bioenvision stockholder meet on Oct 22 - Oct 10, 2007 In May, Genzyme had said it agreed to acquire Bioenvision for about $345 million in cash to gain exclusive rights to clofarabine, a cancer treatment for Reuters Verdict delayed on Genzyme bid for Bioenvision - Oct 4, 2007 The companies share the rights to clofarabine, a treatment for a type of leukemia. By purchasing Bioenvision, Genzyme would gain full control over the drug. Boston Globe, Proxy Briefs (Corrected Version) - Oct 8, 2007 27 that $5.60 was the acquiring company's best and final offer, and that it is fair given the risks involved in Bioenvision, the maker of clofarabine, Hedgeworld (subscription), Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per ... - Sep 27, 2007 We now all know that clofarabine will not be approved in adult AML in the European Union until 2008, at the earliest." Genzyme added that the merger CNNMoney.com Big Bioenvision Holder to Vote Against Merger - Oct 1, 2007 ...to six months the company should be better positioned to work with an independent investment bank due to the potential approval of clofarabine in 2008. TheStreet.com SCO Capital to Vote No on Genzyme - Oct 1, 2007 We remainhighly confident that clofarabine will be approved in the EuropeanUnion for the treatment of adult AML in 2008. We believe Bioenvisionwill be well Ad-Hoc-News (Pressemitteilung), Genzyme: Bioenvision offer stands - Sep 27, 2007 The two companies jointly developed clofarabine, a drug marketed in Europe to treat a form of leukemia in pediatric patients. Genzyme has the rights to Bizjournals.com, Genzyme Says Bioenvision Bid Is Its 'Best and Final' Offer - Sep 27, 2007 ...and our detailed understanding of the risks associated with, and investment required for, the further development of clofarabine. Wall Street Journal Genzyme says will not revise offer price for Bioenvision - Sep 27, 2007 The company said this was its best and final offer, noting that Clofarabine will not be approved in adult acute myeloid leukemia in the European Union until Reuters SCO Capital to Vote No on Genzyme Acquisition of Bioenvision ... - Oct 1, 2007 We remain highly confident that clofarabine will be approved in the European Union for the treatment of adult AML in 2008. We believe Bioenvision will be Business Wire (press release), Genzyme to Bioenvision Board: Acquisition Offer Price Will Not be ... - Sep 27, 2007 ...and have argued that Genzyme’s current rights to Bioenvision’s leukemia drug clofarabine—the big prize in the would-be merger—should be revoked. xconomy Genzyme Confirms Purchase Price For Bioenvision - Update - Sep 27, 2007 Further, Genzyme said its is aware of the risks in detail associated with and also understand the requirement of investments for clofarabine intended for Trading Markets, Bioenvision Inc. lower, Genzyme reaffirms offer - Sep 27, 2007 New York-based Bioenvision is developing clofarabine, a drug for the treatment of acute lymphoblastic leukemia. Genzyme announced that it has sent a letter SmallCapInvestor Genzyme, Bioenvision merger on the rocks - Oct 2, 2007 The two companies are already business partners as they share rights to clofarabine, a drug that treats a type of leukaemia in children. BiopharmaReporter.com, Bioenvision investors to vote again - Oct 10, 2007 Genzyme and Bioenvision already work closely because they share the rights to clofarabine, a leukemia treatment. By purchasing Bioenvision, Genzyme would Boston Globe, Delaware Court Approves Bioenvision, Genzyme Joint Petition - Oct 10, 2007 Bioenvision's product pipeline is focused on: Evoltra(R) (clofarabine) and Modrenal(R). For more information on Bioenvision please visit our website at CNNMoney.com Bioenvision Adjourns Special Meeting of Stockholders - Oct 5, 2007 Bioenvision’s product pipeline is focused on: Evoltra® (clofarabine) and Modrenal®. For more information on Bioenvision please visit our website at WELT ONLINE, Apple: Shinier Than Ever - Sep 21, 2007 The prize Genzyme seeks is exclusive rights to Clofarabine, a treatment for acute lymphoblastic leukemia, co-developed by Genzyme and Bioenvision. BusinessWeek Genzyme Takeover Bid for Bioenvision Still Alive as Special ... - Oct 4, 2007 SCO also is also seeking to terminate Genzyme’s current rights to Bioenvision’s leukemia drug clofarabine. The Associated Press reported today that xconomy Genzyme faces ire of FDA over manufacturing in France - Oct 3, 2007 ...able to renegotiate any sale and get a higher price based on the likelihood of the leukaemia drug Clolar (clofarabine) getting US approval in 2008. Pharma Times (subscription), The List: Innovative Models On Which To Build Biotech - Sep 26, 2007 Armstrong said its lead product, Clofarabine, was approved late last year, and the company now resides on Nasdaq. To date, Bioaccelerate has created 12 BioWorld Online, Elliott 'Extremely Dissatisfied' With Genzyme Bid for Bioenvision ... - 06 Sep 2007 Furthermore, in evaluating clofarabine, Elliott retained expert life science consultants to complete their own, independent projections. CNNMoney.com Bioenvision Provides Evoltra(R) (clofarabine) Regulatory Update - Aug 16, 2007 The AML 16 trial, sponsored by the National Cancer Research Institute (UK), randomizes clofarabine against the standard of care (low-dose cytarabine) for Genetic Engineering News (press release), Market Report -- In Play (BIVN) - Aug 16, 2007 ...the status of its Marketing Authorization Application to the European Medicines Evaluation Agency to include a new indication for Evoltra (clofarabine). MSN Money Former Bioenvision Exec Sues for $108 Million; Genzyme Biding Its ... - Aug 23, 2007 He notes that Genzyme already has North American rights to the leukemia drug, clofarabine, so it makes perfect sense for the company to want to take over xconomy Special Vote Called for on Genzyme’s Takeover Bid for Bioenvision ... - Aug 20, 2007 It also called for terminating Genzyme’s rights to Bioenvision’s leukemia drug, clofarabine. Genzyme countered that it has assurances SCO does not have xconomy Bioenvision Investor to Name 2 Directors - Jul 11, 2007 Forbes,In addition to the two board appointments, Rouhandeh proposed a plan to increase the value of Bioenvision and its pediatric leukemia treatment, clofarabine. Leukaemia patient hopes to get treatment in time - Jul 26, 2007 The Brunei Times,...is still hoping that the Raja Isteri Pengiran Anak Saleha (Ripas) Hospital will get the Clofarabine, the medication needed for his treatment in time. Genzyme nets 22-per cent stake in Bioenvision - Jul 14, 2007 domain-B,Genzyme CEO Henri Termeer said buying Bioenvision and clofarabine would serve as a cornerstone of a cancer treatment business. Genzyme gained the North Genzyme Fires Back, Says It Will Block Addition of New Bioenvision ... - Jul 17, 2007 xconomyThe letter also called for a management overhaul and revocation of Genzyme’s existing sub-license to Bioenvision’s leukemia drug clofarabine in the US and Genzyme extends tender offer for Bioenvision - 02 Jul 2007 Bizjournals.com,The offer was initially opposed by Bioenvision's largest shareholder The two companies have jointly developed clofarabine, marketed in Europe to treat a Move to block acquisition of Bioenvision withdrawn, Genzyme says - Jul 1, 2007 The News Journal,Genzyme, based in Cambridge, Mass., made its offer on May 29 to acquire Bioenvision and get full access to the company's leukemia drug, clofarabine. Bioenvision Investor Criticizes Board - Jun 5, 2007 Forbes,In Tuesday's letter, Rouhandeh noted that Bioenvision stock is trading near a four-year low and that clofarabine may receive market approval within months. 'Little guys' fight Genzyme buyout - Jun 7, 2007 Boston Globe,Bioenvision owns the rights to a leukemia drug called clofarabine, and large biotechnology companies such as Genzyme frequently buy smaller companies to Genzyme no longer facing challenge to Bioenvision merger - Jun 27, 2007 MSN MoneyThe two companies have jointly developed clofarabine, marketed in Europe to treat a form of leukemia in pediatric patients and in the US and Canada as Genzyme Reveals Withdrawal Of Motion For Preliminary Injunction ... - Jun 27, 2007 RTT News,Through the acquisition, the company expects to gain exclusive, worldwide rights to clofarabine for the treatment of acute lymphoblastic leukemia or ALL in Good news leads to analyst love for drugmaker - Jun 10, 2007 Asbury Park Press,Genzyme also announced May 29 that it would acquire Bioenvision for $345 million in cash, a firm that the company has partnered with to launch clofarabine, Biotech Remained Flat in May - Jun 4, 2007 PR Newswire (press release),Genzyme said the move helps enhance its oncology offerings because it will receive exclusive, worldwide rights to clofarabine, a drug Bioenvision and : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |